Results 251 to 260 of about 131,254 (306)

Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System. [PDF]

Immun Inflamm Dis
Yao SY, Du MQ, Yang H, Zeng QM, Zhou H, Zhang X, Kazuo S, Liu J, Lin LX, Kang XH, Jiang DY, Peng Y.   +11 more
europepmc   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy. [PDF]

Int J Mol Sci
Cohen I, Lebel E, Grisariu S, Avni B, Kfir-Erenfeld S, Asherie N, Zimran E, Vainstein V, Assayag M, Sharon TD, Alexander-Shani R, Bessig N, Shehadeh A, Ishtay A, Schlossberg M, Pick M, Gatt ME, Bdolah-Abram T, Stepensky P, Elias S.   +19 more
europepmc   +1 more source

Chimeric antigen receptor therapy for hepatocellular carcinoma

Seminars in Immunology
Lorenz Kocheise, Mohamed-Reda Benmebarek, Mitchell Ho, Tim F. Greten   +3 more
openaire   +2 more sources

Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis

British Journal of Haematology, EarlyView.
Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You   +7 more
wiley   +1 more source

Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. [PDF]

World J Clin Oncol
Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F.   +4 more
europepmc   +1 more source

Chimeric antigen receptor-based cell therapy for treating urological tumors. [PDF]

Curr Urol
Tang H, Guo L, Zhang W, Tang D.
europepmc   +1 more source

Chimeric antigen receptor (CAR) therapies for precise eradication of pathogenic cells in autoimmunity. [PDF]

Arthritis Res Ther
Kalliolias GD, Basdra EK, Papavassiliou AG.   +2 more
europepmc   +1 more source

A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends. [PDF]

Biomark Res
Lai C, Hu J, Wu Z, He K, Li J, Zhu W, Liu C, He W, Xu K.   +8 more
europepmc   +1 more source

Teclistamab interference with anti-BCMA chimeric antigen receptor T-cell detection by flow cytometry: duration and clinical implications. [PDF]

Leukemia
Schadt J, von Bonin M, Oelschlägel U, Teipel R, Epp K, Saalfeld FC, Schulze F, Heuschkel S, Bornhäuser M, Röhnert MA.   +9 more
europepmc   +1 more source